GBP Capital has a total of 12 patents globally, out of which 7 have been granted. Of these 12 patents, all their patents are dead. Europe is where GBP Capital has filed the maximum number of patents, followed by Austria and New Zealand. Parallelly, the United States of America seems to be the main focused R&D centre and also is the origin country of GBP Capital.
GBP Capital was founded in 2002. GBP Capital provides venture funding and assistance to early and mid-stage life science companies. They go after businesses that have cutting-edge diagnostic, therapeutic, and medical device techniques that will alter how healthcare innovation is done in the future.
Do read about some of the most popular patents of GBP Capital which have been covered by us in this article and also you can find GBP Capital patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over GBP Capital patent portfolio.
How many patents does GBP Capital have?
GBP Capital has a total of 12 patents globally. These patents belong to 6 unique patent families. Out of 12 patents, 0 patents are active.
How Many Patents did GBP Capital File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||GBP Capital Applications Filed||GBP Capital Patents Granted|
How many GBP Capital patents are Alive/Dead?
All the patents of GBP Capital are dead.
How Many Patents did GBP Capital File in Different Countries?
Countries in which GBP Capital Filed Patents
Where are Research Centers of GBP Capital Patents Located?
List of GBP Capital patents
|GBP Capital Patents||Title|
|EP1849873B1||Method And Means For Producing High Titer, Safe, Recombinant Lentivirus Vectors|
|EP0710280B1||Method For Production Of High Titer Virus And High Efficiency Retroviral Mediated Transduction Of Mammalian Cells|
|EP1395293B1||Lentiviral Vectors Encoding Clotting Factors For Gene Therapy|
|EP1497437A4||Lentiviral Vector Particles Resistant To Complement Inactivation|
|AT528406T||Method And Means For Production Of Safe, High Title Recombinant Lentivirus Vectors|
|AT485367T||Procedures For The Production Of High Virus Levels And The Highly Efficient Transduction Of Mammalian Cells By Retrovirus|
|AT437221T||Lentiviral Vectors Encoding Colotting Factors For Gene Therapy|
|JP4979851B2||How To Generate High-Titer, Safe Recombinant Lentiviral Vectors|
|IL146144A||Lentiviral Vector System, Use Thereof And Methods Of Producing A Recombinant Lentivirus|
|SG73931B||Method And Means For Producing High Titer, Safe, Recombinant Lentivirus Vectors|
|NZ505145B||High-Efficiency Retroviral Packaging System|
|AU742403B2||High-Efficiency Retroviral Packaging System|